Abstract
Cardiovascular diseases are the major cause of death and a significant cause of disability in the Western world and more recently threaten to pose an increasing health burden on developing nations. People with pre-existent vascular disease are those at highest risk for adverse cardiovascular outcomes and require aggressive secondary preventive therapies. Large strides have been made in the development of pharmacologic agents that intervene on various pathways implicated in atherogenesis, thus offering the ability to greatly impact on disease progression and to prevent events. Compelling data derived primarily from randomized controlled trials have shown the benefits of aspirin (or antiplatelet agents) and angiotensin converting enzyme (ACE) inhibitors (A), beta-blockers and blood pressure (B) and cholesterol-lowering drugs (C), particularly statins, in preventing recurrent events and improving survival. Taken together these data are the foundation for the simple, but important advice for secondary prevention - the ABCs. In addition, the evidence for the central role of lifestyle factors as determinants of risk has lead to increased efforts towards developing interventions aimed at modifying lifestyle patterns. Today, the biggest challenge remains in the implementation of proven effective therapies. Our focus should turn to educating physicians and patients alike regarding available therapies and their indications. In addition systematic, sustainable and globally applicable approaches to the secondary prevention of cardiovascular diseases need to be developed to truly realize the vast potential benefits of existing therapies.
Keywords: Cardiovascular disease, cardiovascular prevention, myocardial infarction, stroke, statins, ACE inhibitors, angiotensin receptor blockers, ntiplatelet agents, beta-blockers, cardiac rehabilitation
Current Vascular Pharmacology
Title: Drug Therapies in the Secondary Prevention of Cardiovascular Diseases:Successes, Shortcomings and Future Directions
Volume: 4 Issue: 3
Author(s): Eva Lonn and Jasmine Grewal
Affiliation:
Keywords: Cardiovascular disease, cardiovascular prevention, myocardial infarction, stroke, statins, ACE inhibitors, angiotensin receptor blockers, ntiplatelet agents, beta-blockers, cardiac rehabilitation
Abstract: Cardiovascular diseases are the major cause of death and a significant cause of disability in the Western world and more recently threaten to pose an increasing health burden on developing nations. People with pre-existent vascular disease are those at highest risk for adverse cardiovascular outcomes and require aggressive secondary preventive therapies. Large strides have been made in the development of pharmacologic agents that intervene on various pathways implicated in atherogenesis, thus offering the ability to greatly impact on disease progression and to prevent events. Compelling data derived primarily from randomized controlled trials have shown the benefits of aspirin (or antiplatelet agents) and angiotensin converting enzyme (ACE) inhibitors (A), beta-blockers and blood pressure (B) and cholesterol-lowering drugs (C), particularly statins, in preventing recurrent events and improving survival. Taken together these data are the foundation for the simple, but important advice for secondary prevention - the ABCs. In addition, the evidence for the central role of lifestyle factors as determinants of risk has lead to increased efforts towards developing interventions aimed at modifying lifestyle patterns. Today, the biggest challenge remains in the implementation of proven effective therapies. Our focus should turn to educating physicians and patients alike regarding available therapies and their indications. In addition systematic, sustainable and globally applicable approaches to the secondary prevention of cardiovascular diseases need to be developed to truly realize the vast potential benefits of existing therapies.
Export Options
About this article
Cite this article as:
Lonn Eva and Grewal Jasmine, Drug Therapies in the Secondary Prevention of Cardiovascular Diseases:Successes, Shortcomings and Future Directions, Current Vascular Pharmacology 2006; 4 (3) . https://dx.doi.org/10.2174/157016106777698360
DOI https://dx.doi.org/10.2174/157016106777698360 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Smoking and Cardiovascular System: Cellular Features of the Damage
Current Pharmaceutical Design Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Blood Pressure Lowering Treatment in Patients with Carotid Artery Stenosis
Current Hypertension Reviews Endothelins Role in the Control of the Acute Phase of Trypanosoma cruzi Infection
Mini-Reviews in Medicinal Chemistry Neuroprotection by Diazoxide in Animal Models for Cerebrovascular Disorders
Vascular Disease Prevention (Discontinued) Evaluation of Drug Transporter Interactions in Drug Discovery and Development
Combinatorial Chemistry & High Throughput Screening Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area
Current Psychiatry Reviews A Brief History of ‘Lone’ Atrial Fibrillation: From ‘A Peculiar Pulse Irregularity’ to a Modern Public Health Concern
Current Pharmaceutical Design Adoptive Regulatory T-cell Therapy Attenuates Subarachnoid Hemor-rhage-induced Cerebral Inflammation by Suppressing TLR4/NF-B Signaling Pathway
Current Neurovascular Research Safety of Dabigatran in an Elderly Population: Single Center Experience in Italy
Current Drug Safety Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets Clinical Use of Intracoronary Gene Transfer of Fibroblast Growth Factor for Coronary Artery Disease
Current Gene Therapy Insulin Resistance, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prognostic Significance of Asymptomatic Myocardial Ischemia in Women vs. Men
Current Pharmaceutical Design Anticoagulant Therapy in Pregnant Patients with Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Purines as Neurotransmitters and Neuromodulators in Blood Vessels
Current Vascular Pharmacology Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Hypertension in Pregnancy: Pathophysiology & Management Strategies
Current Pharmaceutical Design Why Not All Hypertensive Patients Are Tachycardic at Rest?
Current Pharmaceutical Design Macrocyclic Compounds: Emerging Opportunities for Current Drug Discovery
Current Pharmaceutical Design